Information Provided By:
Fly News Breaks for August 15, 2019
Aug 15, 2019 | 08:14 EDT
Wells Fargo analyst David Maris lowered his price target for Allergan (AGN) to $176 from $188 after the company reported Q2 results. Overall, the analyst believes the quarter was "not perfect," as Allergan took an impairment charge, and CoolSculpting continues to face pressure, but there were no major surprises in his view and nothing in the quarter makes him incrementally more concerned that the AbbVie (ABBV) deal will close. Maris reiterates an Outperform rating on Allergan's shares.